BioLineRx and Hemispherian to showcase preclinical data for first-in-class glioblastoma asset at ASCO 2026
BioLineRx (NASDAQ:BLRX) and Hemispherian announced that two abstracts featuring their experimental oncology compound, GLIX1, will be published at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.










